Citation & Authors
Thorax. 2024;79(11):1017-1023.
ABSTRACT · RESEARCH SUMMARY
Research summary
This matched Taiwanese National Health Insurance cohort analyzed patients with type 2 diabetes and COPD. GLP-1 receptor agonist use was associated with lower risks of death (aHR 0.46; 95% CI 0.38–0.56), cardiovascular events, noninvasive and invasive ventilation, and bacterial pneumonia. Several subgroup and treatment-duration analyses supported the association, but the evidence remains observational.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
